ライフサイエンスコーパス: magnesium sulfate

1 7-TBI, 2000 mM NaLac and 8-TBI-500 mM NaLac+magnesium sulfate.

2 factors, hypothermia, and administration of magnesium sulfate.

3 ence of CP or MR than those not exposed (CP: magnesium sulfate, 0.9%, no magnesium sulfate, 7.7%, cru

4 dds ratio [OR], 0.11, 95% CI, 0.02-0.81; MR: magnesium sulfate, 1.8%, no magnesium sulfate, 5.8%, cru

5 Patients received a "test dose" of either magnesium sulfate (2 g, 8 mmol) or placebo (5% dextrose

6 ly to have a seizure than those who received magnesium sulfate (21 of 819 [2.6 percent] vs. 7 of 831

7 , 0.02-0.81; MR: magnesium sulfate, 1.8%, no magnesium sulfate, 5.8%, crude OR, 0.30, 95% CI, 0.07-1.

8 not exposed (CP: magnesium sulfate, 0.9%, no magnesium sulfate, 7.7%, crude odds ratio [OR], 0.11, 95

9 Magnesium sulfate administered according to the above re

10 ween 24 and 31 weeks of gestation to receive magnesium sulfate, administered intravenously as a 6-g b

11 ical and experimental evidence as to whether magnesium sulfate, administered soon before premature bi

12 re were no complications associated with the magnesium sulfate administration.

13 tests the hypothesis that administration of magnesium sulfate, an antagonist of the NMDA receptor io

14 ors found no association between exposure to magnesium sulfate and cerebral palsy risk (odds ratio =

15 basaltic rocks, sulfate minerals (including magnesium sulfate and jarosite) that constitute several

16 Comparing the magnesium sulfate and placebo groups revealed no statist

17 :water (2:1) as extraction solvent and dried magnesium sulfate and sodium chloride as salts.

18 added to the botanical along with anhydrous magnesium sulfate and sodium chloride for extraction, fo

19 th acetonitrile after the addition of salts (magnesium sulfate and sodium chloride), followed by a cl

20 After salting out by shaking with anhydrous magnesium sulfate and sodium chloride, 1 mL of acetonitr

21 ry spectra of hydrated salt minerals such as magnesium sulfates and sodium carbonates and mixtures of

22 0-500 mg IV thiamine every 8 hours, 64 mg/kg magnesium sulfate (approximately 4-5 g for most adult pa

23 Fetal exposure to magnesium sulfate before anticipated early preterm deliv

24 Research suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the

25 hose found on Europa, that is, mostly frozen magnesium sulfate brines that are derived from a subsurf

26 geological environment that contains borate, magnesium, sulfate, calcium, and phosphate in evaporite

27 t appear to be due to selective mortality of magnesium sulfate-exposed infants.

28 t, there was no association between prenatal magnesium sulfate exposure and infant mortality (adjuste

29 rs examined the relation between intrapartum magnesium sulfate exposure and risk of cerebral palsy in

30 arily, to investigate the effect of prenatal magnesium sulfate exposure on VLBW infant mortality.

31 Data on magnesium sulfate exposure, labor and delivery, and infa

32 ng VLBW children is associated with prenatal magnesium sulfate exposure.

33 ne whether nimodipine is more effective than magnesium sulfate for seizure prophylaxis in women with

34 Magnesium sulfate given to pregnant women at imminent ri

35 Antenatal magnesium sulfate given to pregnant women at imminent ri

36 (60 mg orally every 4 hours) or intravenous magnesium sulfate (given according to the institutional

37 ccurred significantly less frequently in the magnesium sulfate group (1.9% vs. 3.5%; relative risk, 0

38 y rate to school age was 14% (88/629) in the magnesium sulfate group and 18% (110/626) in the placebo

39 tcome was not significantly different in the magnesium sulfate group and the placebo group (11.3% and

40 More women in the magnesium sulfate group than in the nimodipine group nee

41 ong Atlanta-born survivors, those exposed to magnesium sulfate had a lower prevalence of CP or MR tha

42 Statins, endothelin antagonists, and magnesium sulfate infusion are among the novel strategie

43 Magnesium sulfate is more effective than nimodipine for

44 Magnesium sulfate is neuroprotective in preclinical mode

45 Notably, pretreatment of pregnant dams with magnesium sulfate is sufficient to prevent the early inf

46 radish peroxidase, starch, vitamin K, hemin, magnesium sulfate, manganese sulfate, and horse serum.

47 Magnesium sulfate may prevent eclampsia by reducing cere

48 sample preparation, diluting the sample with magnesium sulfate (MgSO(4)) previous to COD determinatio

49 Based on preclinical investigations, magnesium sulfate (MgSO4) has gained interest as a neuro

50 rose, and shikimic acid) and inorganic gels (magnesium sulfate, MgSO4).

51 e unusual areas are consistent with hydrated magnesium sulfates mixed with dark background material,

52 omized to receive either placebo (n = 15) or magnesium sulfate (n = 17).

53 spected stroke to receive either intravenous magnesium sulfate or placebo, beginning within 2 hours a

54 igned to Ca/Mg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo,

55 a 2-mL centrifuge tube containing anhydrous magnesium sulfate, primary secondary amine sorbent, and

56 Patients receiving magnesium sulfate showed a statistically significant inc

57 Prehospital initiation of magnesium sulfate therapy was safe and allowed the start

58 Continuous nebulization, addition of magnesium sulfate to SABA, and levosalbutamol compared t

59 However, in the magnesium sulfate-treated group the Bax:Bcl-2 ratio was

60 c controls (Nx), untreated hypoxic (Hx), and magnesium sulfate-treated hypoxic (Mg-Hx) groups.

61 We suggest that magnesium sulfate treatment before and during hypoxia ma

62 The data demonstrate that magnesium sulfate treatment prevents both the hypoxia-in

63 associated with nimodipine, as compared with magnesium sulfate, was 3.2 (95 percent confidence interv

64 onal studies have reported an association of magnesium sulfate with lower rate of cerebral palsy, whe

65 ters in Australia and New Zealand, comparing magnesium sulfate with placebo given to pregnant women (